Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2018-08-01
2031-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Angelman Syndrome Natural History Study-FAST UK
NCT05100810
The Global Angelman Syndrome Registry
NCT05293184
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
NCT04259281
Natural History Study of Participants With Sanfilippo Syndrome Type IIIC
NCT05825131
Angelman Natural History Study - FAST Spain
NCT06115109
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Diego
OTHER
Angelman Syndrome Biomarker & Outcome Measure Consortium (A-BOM)
UNKNOWN
Food and Drug Administration (FDA)
FED
Angelman Syndrome Foundation Canada
UNKNOWN
Foundation for Angelman Syndrome Therapeutics Canada
UNKNOWN
Foundation for Angelman Syndrome Therapeutics
UNKNOWN
Angelman Syndrome Foundation, Inc.
OTHER
Boston Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wen-Hann Tan
Attending Physician in Genetics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wen-Hann Tan, BMBS
Role: STUDY_CHAIR
Boston Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars-Sinai Guerin Children's
Los Angeles, California, United States
Rady Children's Hospital, San Diego
San Diego, California, United States
Children's Hospital Colorado, Anschutz Medical Campus
Aurora, Colorado, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Rush University Children's Hospital
Chicago, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
The Carolina Institute for Developmental Disabilities
Carrboro, North Carolina, United States
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, United States
Alberta Children's Hospital
Calgary, Alberta, Canada
BC Children's Hospital
Vancouver, British Columbia, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-P00025249
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.